Intravenous immune globulin in primary immunodeficiency

Area of Science:

• Immunology
• Pharmacology

Background:

• Intravenous immunoglobulin (IVIG) preparations are crucial for treating severe antibody deficiencies.
• Current research highlights the need for more comparative trials on IVIG efficacy and duration.
• Optimal dosing strategies and trough IgG levels are subjects of ongoing clinical consensus.

Purpose of the Study:

• To review the efficacy and safety of IVIG in treating antibody deficiencies.
• To assess adverse reactions and potential risks associated with IVIG therapy.
• To evaluate home self-infusion as a viable treatment alternative.

Main Methods:

• Review of existing clinical studies and consensus guidelines on IVIG therapy.
• Analysis of adverse event profiles, including anaphylactoid reactions and viral transmission risks.
• Evaluation of safety and cost-effectiveness data for home-based IVIG administration.

Main Results:

• High-dose IVIG (≥400 mg/kg/month) is generally superior to lower doses, with a target trough IgG level >5 g/l.
• Mild adverse reactions are common, but severe reactions are rare, except in IgA-deficient patients.
• IVIG carries a minimal risk of viral transmission (e.g., hepatitis C), but not HIV or hepatitis B. Home therapy is safe and cost-effective.

Conclusions:

• High-dose IVIG is an effective treatment for antibody deficiencies, with home self-infusion offering a safe and economical option.
• Careful patient selection and monitoring are essential to minimize risks associated with IVIG therapy.
• Further comparative studies are needed to refine IVIG treatment protocols and preparation selection.